Thomas Braun, PhD
- Professor Of Biostatistics
- M4063 SPH II
- 1415 Washington Heights
- Ann Arbor, Michigan 48109-2029
Thomas (Tom) is a Professor in the Department of Biostatistics. He received his PhD in Biostatistics from the University of Washington in 1999. Dr. Braun is an international expert in the design of Bayesian adaptive designs for oncology clinical trials, and he has more recently expanded his research into snSMART designs for clinical trials for rare diseases. Dr. Braun has collaborated with a variety of medical and public health investigators, including bone marrow transplantation, cancer of the mouth, breast, and lungs, periodontal disease, and development of anthrax vaccines. Tom also is an active member in University of Michigan committees working to address issues of incivility, rankism, and harassment in academia, and he also active in developing new pedagogy for teaching biostatistics and data science.
- BIOSTAT601 Probability and Distribution Theory
- BIOSTAT685 Elements of Nonparametric Statistics
- BIOSTAT810 Approaches to the Responsible Practice of Biostatistics
- PhD, Biostatistics, University of Washington, 1999
- M.S., Biostatistics, University of Washington, 1996
- B.B.A, Actuarial Science, University of Wisconsin-Madison, 1990
- Adaptive Phase I Trial Designs in Oncology
Sponsor: University of Michigan Comprehensive Cancer Center (UMCCC)
Many of the motivating examples for my research develop from my collaborations with the UMCCC Bone Marrow Transplantation and their studies of acute-graft-versus-host disease (aGVHD) and relapse in allogeneic bone marrow transplant recipients.
Although sophisticated designs for dose-finding in Phase I trials have grown in number over the past two decades, little attention has been given to determining how many administrations of the dose can be given, as well as when each dose should be given. I have developed statistical models that allow for assessing the toxicity and efficacy of multiple administration schedules of an agent as well as determining which of the schedules leads to optimal rates of toxicity and/or efficacy. The schedule finding algorithm relies upon Bayesian methods that require the user to develop a prior distribution that is sufficiently informative for the beginning of the trial, but sufficiently non-informative for the end of the trial. Therefore, my research also focuses upon how to derive usable prior distributions from basic information supplied by investigators, allowing statisticians and clinicians to "communicate" more effectively.
I am also researching: (1) models for studies of two or more agents, one of which is often a biologic target used to weaken the cancer and "boost" the myeloablative ability of standard chemotherapy and radiation; (2) the effect of ignoring and the benefit of incorporating patient heterogeneity on the performance of adaptive designs; (3) models for inclusion of mild, non-dose-limiting toxicities into determining the overall probability of dose-limiting toxicities (DLTs); (4) the impact of premature death, a competing risk for DLT, on the performance of adaptive designs.
This research is partially funded through my R01 grant from the National Institutes of Health entitled "Statistical Methods and Issues for Implementing Adaptive Phase I Trials"
- Multivariate Longitudinal Modeling of Periodontal Outcomes
Sponsor: Michigan Center for Oral Health Research (MCOHR)
I am the primary statistician for clinical studies at the University of Michigan School of Dentistry. Much of my collaborative effort involves prediction, diagnosis, and treatment of periodontal disease. Most periodontal studies collect data with multiple levels of correlation including (a) the same outcome, i.e. clinical attachment level (CAL), pocket depth (PD), and bleeding on probing (BOP), measured longitudinally on the same site, (b) different outcomes measured longitudinally on the same site, (c) multiple sites measured on the same tooth, and (d) multiple teeth measured on the same subject. However, hierarchical data analysis methods like random effects models and GEE have yet to be the "gold-standard" in this setting. Much of my research is focused upon increasing the use of these data analysis techniques in periodontal studies, as well as developing new approaches for correlated data useful for this setting, such as Bayesian spatial modeling and permutation tests.
A secondary area of interest is methodology is developing predictive models for the progression of periodontal disease and gingivitis using longitudinally measured site- and tooth-specific salivary biomarkers and plaque baterial counts, either through regression modeling strategies or multivariate clustering algorithms.
- Shamoun M, Braun T, Magenau J, Choi SW, Reddy P, Pawarode A, Riwes M, Kitko C, Anand S, Ghosh M, Vander Lugt M, Bonifant C, Abusin G, Parkin B, Peltier D, Yanik G (2019) The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD). Biology of Blood and Marrow Transplantation 25(3): S26-S27.
- Magenau J, Braun T, Gatza E, Churay T, Mazzoli A, Chappell G, Runaas L, Anand S, Ghosh M, Riwes M, Pawarode A, Yanik G, Reddy P, Choi SW (2019). Impact of Individual Vs. Composite Endpoints for Prediction of Long-Term Survival in Gvhd Clinical Trials. Research Biology of Blood and Marrow Transplantation 25(3): S68-S69.
- Muenz D, Taylor J, Braun T (2019) Phase I–II trial design for biologic agents using conditional auto‐regressive models for toxicity and efficacy. Journal of the Royal Statistical Society: Series C.
- Magenau J, Braun T, Gatza E, Churay T, Mazzoli A, Chappell G, Brisson J, Runaas L, Anand S, Ghosh M, Riwes M, Pawarode A, Yanik G, Reddy P, Choi SW (2019). Assessment of Individual vs. Composite Endpoints of Acute GVHD in Determining Long-Term Survival after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation
- Wei B, Braun T, Tamura R, Kidwell K (2018) A Bayesian analysis of small n sequential multiple assignment randomized trials (snSMARTs). Statistics in Medicine 37(26) 3723-3732.
- Wages N, Braun T (2018). Accuracy, Safety, and Reliability of Novel Phase I Designs. Clinical Cancer Research 24(21): 5482-5482.
- Braun T (2018). Motivating sample sizes in adaptive Phase I trials via Bayesian posterior credible intervals. Biometrics 74(3): 1065-1071.
- Segal B, Braun T, Elliott M, Jiang H (2018). Fast approximation of small p‐values in permutation tests by partitioning the permutations. Biometrics 74(1):196-206.
- Boonstra P, Braun T, Taylor J, Kidwell K, Bellile E, Daignault S, Zhao L, Griffith K, Lawrence T, Kalemkerian GP, Schipper M (2017). Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts. Annals of Oncology 28(7):1427-1435.
- Braun T, Kang S, Taylor J (2016) A phase I/II trial design when response is unobserved in subjects with dose-limiting toxicity. Statistical Methods in Medical Research 25 (2): 659-673.
- Biometrics Society
- American Statistical Association